This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BASi Launches Culex NxT Next Generation In Vivo Automated Sampling System

BASi (Bioanalytical Systems, Inc.) (NASDAQ:BASI) today announced the launch of Culex ® NxT, the latest generation of the Company’s proprietary in vivo automated sampling system. The Company is now taking orders for Culex NxT and expects to begin shipping in January.

Developed by BASi to collect pharmacokinetic and pharmacodynamic data, the Culex system can automatically collect blood, bile, metabolites, dialysates and more from awake and freely moving animals as small as mice and as large as swine. The system is used by nine of the world’s top ten pharmaceutical companies, universities, and contract research organizations.

"Scientists choose Culex over manual sampling because it delivers better data, which leads to better decision-making," said Candace Rohde-Johnson, director of BASi's Instruments Division. "Incorporating innovative hardware and software improvements, the new Culex NxT has the same small footprint, robust design and ease of use of the original, providing its users peace of mind when away from the lab. Culex’s ability to run experiments around the clock versus just during business hours significantly increases our clients' efficiency and productivity in the early stages of drug discovery, including safety pharmacology."

Rohde-Johnson continued, "Culex NxT incorporates what we have learned from Culex enthusiasts in industry and academia who share best practices, attend annual user meetings and provide their insights online. The improved tubing sets, optics, wireless notifications, quieter operation and in-line glucose monitoring are just some of the improvements built on this foundation, solidifying Culex as the preferred instrumentation for automated sampling. We've also made it easy for current owners to seamlessly and cost-effectively upgrade their existing systems."

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs